Panelists discuss how the rapid adoption of subcutaneous (SubQ) oncology therapies creates challenges around clinical autonomy, infusion center sustainability, patient experience, and reimbursement ...

SubQ-8 is based on Octapharma’s human cell line-derived rFVIII product simoctocog alpha combined with a fragment of the von Willebrand Factor (VWF) protein, and harnesses the protective power of ...

SubQ-8 combines simoctocog alfa, a human cell line ... the rationale for the development of SubQ-8 and the challenge of achieving sufficient FVIII bioavailability after subcutaneous infusion.

Panelists discuss how subcutaneous (SubQ) oncology treatments are reshaping clinic operations by improving infusion chair utilization, enabling flexible scheduling, streamlining pharmacy workflows ...

BD (Becton, Dickinson and Company), a leading global medical technology company, announces the approval of the BD Saf-T-Intima Safety Integrated IV Catheter System for use in subcutaneous infusion ...

Now, Vyalev (foscarbidopa and foslevodopa) has become the first subcutaneous 24-hour continuous infusion of levodopa-based therapy for the treatment of motor fluctuations in advanced Parkinson's ...

OCARINA II randomized 236 MS patients to 920 mg subcutaneous injection (118 participants) or 600 mg IV infusion (118 participants). Infusions were administered at 300 mg at two IV sessions, 2 ...

Compared with oral administration, continuous subcutaneous infusion of carbidopa/levodopa was linked to nearly 2 more hours of “on” time without dyskinesia in adults with Parkinson’s disease ...

The maximum infusion rate of the subcutaneous pump used was 0.35 mL/h, and we used a concentration of glucose of 10%, maximizing the rate that could be achieved for the subcutaneous tracer to 35 mg/h.

Octapharma Share Promising Preclinical Data for SubQ-8, a Novel Subcutaneous Recombinant FVIII, at WFH 2018. Tuesday, May 29, 2018 5:13PM IST (11:43AM GMT) ...